Antares Pharma (NASDAQ:ATRS) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Other equities analysts also recently issued research reports about the stock. ValuEngine downgraded shares of Antares Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Piper Jaffray Companies reiterated a “buy” rating and set a $4.00 price objective on shares of Antares Pharma in a research report on Friday, August 17th. Finally, HC Wainwright set a $5.00 price objective on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Friday, August 17th.

ATRS stock opened at $3.36 on Friday. The firm has a market cap of $538.43 million, a PE ratio of -30.55 and a beta of 0.34. Antares Pharma has a 52-week low of $1.58 and a 52-week high of $4.09. The company has a quick ratio of 1.89, a current ratio of 2.33 and a debt-to-equity ratio of 1.01.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). The business had revenue of $14.16 million for the quarter, compared to the consensus estimate of $13.70 million. Antares Pharma had a negative net margin of 35.53% and a negative return on equity of 64.96%. research analysts predict that Antares Pharma will post -0.1 EPS for the current year.

In other news, Director Jacques Gonella sold 250,493 shares of the stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $3.09, for a total transaction of $774,023.37. Following the completion of the sale, the director now directly owns 10,035,355 shares in the company, valued at $31,009,246.95. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Robert F. Apple sold 43,000 shares of the stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $3.75, for a total transaction of $161,250.00. Following the sale, the chief executive officer now owns 1,573,562 shares of the company’s stock, valued at $5,900,857.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 343,000 shares of company stock valued at $1,088,250. 12.20% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY grew its holdings in Antares Pharma by 127.0% in the second quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock worth $133,000 after purchasing an additional 28,875 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Antares Pharma by 4.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 744,188 shares of the specialty pharmaceutical company’s stock worth $1,921,000 after purchasing an additional 32,626 shares during the period. JW Asset Management LLC grew its holdings in Antares Pharma by 2.8% in the second quarter. JW Asset Management LLC now owns 1,820,524 shares of the specialty pharmaceutical company’s stock worth $4,697,000 after purchasing an additional 50,000 shares during the period. MetLife Investment Advisors LLC grew its holdings in Antares Pharma by 281.1% in the first quarter. MetLife Investment Advisors LLC now owns 71,731 shares of the specialty pharmaceutical company’s stock worth $158,000 after purchasing an additional 52,911 shares during the period. Finally, Northern Trust Corp grew its holdings in Antares Pharma by 7.4% in the second quarter. Northern Trust Corp now owns 1,718,251 shares of the specialty pharmaceutical company’s stock worth $4,433,000 after purchasing an additional 119,091 shares during the period. Institutional investors own 38.92% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

See Also: How do investors use RSI to grade stocks?

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.